Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioCardia, Inc.BCDA · Entity 7752 | Chief Financial Officer | July 02, 2026 | July 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioCardia, Inc.
Report date July 02, 2026 · Filed July 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 114,245 |
Reported balance
After 2026-07-02 transaction · row 1
1 source rowRow 1 · 2026-07-02 · Tax withholding · Disposed 23,125 · Balance 114,245 F1: The reported securities represent the shares that have been withheld by the Issuer to satisfy its income tax, withholding and remittance obligations in connection with the net settlement on July 2, 2026, of the RSUs vested on June 29, 2026 and does not represent a sale by the Reporting Person. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2036-07-06 | Direct | 87,841 |
Reported balance
After 2026-07-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-06 · Grant · Acquired 41,501 · Balance 87,841 F2: The option vests and becomes exercisable as to 1/48th of the shares on August 6, 2026, and each month thereafter, subject to the Reporting Person continuing as a service provider through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent the shares that have been withheld by the Issuer to satisfy its income tax, withholding and remittance obligations in connection with the net settlement on July 2, 2026, of the RSUs vested on June 29, 2026 and does not represent a sale by the Reporting Person.
F2: The option vests and becomes exercisable as to 1/48th of the shares on August 6, 2026, and each month thereafter, subject to the Reporting Person continuing as a service provider through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2026 Filed Jul 8, 2026 02:03 UTC | BioCardia, Inc. BCDA · Entity 7752 | GrantStock Option (right to buy) · Derivative | 41,501 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001437749-26-022968 · rdgdoc.xml · derivative · entry 2 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,841 Underlying: Common stock · 41,501 shares Expires 2036-07-06 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 1/48th of the shares on August 6, 2026, and each month thereafter, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| July 02, 2026 Filed Jul 8, 2026 02:03 UTC | BioCardia, Inc. BCDA · Entity 7752 | Tax withholdingCommon Stock | 23,125 | $1.24 | $28,675.00 |
DisclosureSEC source: 0001437749-26-022968 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,245 F1 · shares: The reported securities represent the shares that have been withheld by the Issuer to satisfy its income tax, withholding and remittance obligations in connection with the net settlement on July 2, 2026, of the RSUs vested on June 29, 2026 and does not represent a sale by the Reporting Person. F1 · price: The reported securities represent the shares that have been withheld by the Issuer to satisfy its income tax, withholding and remittance obligations in connection with the net settlement on July 2, 2026, of the RSUs vested on June 29, 2026 and does not represent a sale by the Reporting Person. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 23:37 UTC | BioCardia, Inc. BCDA · Entity 7752 | GrantCommon Stock | 60,483 | $1.20 | $72,579.60 |
DisclosureSEC source: 0001437749-26-022364 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,370 F1 · shares: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock awarded as compensation in lieu of cash. 100% of the RSUs vested on June 29, 2026. F1 · price: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock awarded as compensation in lieu of cash. 100% of the RSUs vested on June 29, 2026. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:54 UTC | BioCardia, Inc. BCDA · Entity 7752 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001437749-25-037474 · rdgdoc.xml · derivative · entry 3 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,340 Underlying: Common stock · 20,000 shares Expires 2035-12-08 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 1/48th of the shares on January 8, 2026, and each month thereafter, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:54 UTC | BioCardia, Inc. BCDA · Entity 7752 | Tax withholdingCommon Stock | 29,339 | $1.37 | $40,194.43 |
DisclosureSEC source: 0001437749-25-037474 · rdgdoc.xml · nonDerivative · entry 2 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,887 F2 · shares: The reported securities represent the shares that have been withheld by the Issuer to satisfy its income tax, withholding and remittance obligations in connection with the net settlement of the RSUs vested on December 8, 2025 and does not represent a sale by the Reporting Person. F2 · price: The reported securities represent the shares that have been withheld by the Issuer to satisfy its income tax, withholding and remittance obligations in connection with the net settlement of the RSUs vested on December 8, 2025 and does not represent a sale by the Reporting Person. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:54 UTC | BioCardia, Inc. BCDA · Entity 7752 | GrantCommon Stock | 58,276 | $1.37 | $79,838.12 |
DisclosureSEC source: 0001437749-25-037474 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,226 F1 · shares: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock awarded as compensation in lieu of cash. 100% of the RSUs vested on December 8, 2025. F1 · price: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock awarded as compensation in lieu of cash. 100% of the RSUs vested on December 8, 2025. Read SEC document |
| June 30, 2025 Filed Jul 3, 2025 01:03 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseWarrant (right to buy) · Derivative | 4,819 | Not disclosed Strike: $1.95 | Not disclosed |
DisclosureSEC source: 0001437749-25-022065 · rdgdoc.xml · derivative · entry 2 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,275 Underlying: Common Stock · 4,819 shares Expires 2030-06-30 F1 · shares: On June 30, 2025, the Registrant closed a private placement with certain qualified institutional buyers and institutional accredited investors, as well as the Reporting Person, wherein the Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased. F1 · price: On June 30, 2025, the Registrant closed a private placement with certain qualified institutional buyers and institutional accredited investors, as well as the Reporting Person, wherein the Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased. F1 · derivative.underlying_shares: On June 30, 2025, the Registrant closed a private placement with certain qualified institutional buyers and institutional accredited investors, as well as the Reporting Person, wherein the Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased. Read SEC document |
| June 30, 2025 Filed Jul 3, 2025 01:03 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseCommon Stock | 4,819 | $2.08 | $9,999.43 |
DisclosureSEC source: 0001437749-25-022065 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,950 F1 · shares: On June 30, 2025, the Registrant closed a private placement with certain qualified institutional buyers and institutional accredited investors, as well as the Reporting Person, wherein the Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased. F1 · price: On June 30, 2025, the Registrant closed a private placement with certain qualified institutional buyers and institutional accredited investors, as well as the Reporting Person, wherein the Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased. Read SEC document |
| April 23, 2025 Filed Apr 26, 2025 01:38 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseWarrant (right to buy) · Derivative | 13,123 | Not disclosed Strike: $1.91 | Not disclosed |
DisclosureSEC source: 0001437749-25-013200 · rdgdoc.xml · derivative · entry 2 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,456 Underlying: Common Stock · 13,123 shares Expires 2030-04-23 F1 · shares: On April 23, 2025, the Registrant closed a private placement with certain qualified institutional buyers and institutional accredited investors, as well as the Reporting Person, wherein the Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased. F1 · price: On April 23, 2025, the Registrant closed a private placement with certain qualified institutional buyers and institutional accredited investors, as well as the Reporting Person, wherein the Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased. F1 · derivative.underlying_shares: On April 23, 2025, the Registrant closed a private placement with certain qualified institutional buyers and institutional accredited investors, as well as the Reporting Person, wherein the Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased. Read SEC document |
| April 23, 2025 Filed Apr 26, 2025 01:38 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseCommon Stock | 13,123 | $1.91 | $24,999.32 |
DisclosureSEC source: 0001437749-25-013200 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,131 F1 · shares: On April 23, 2025, the Registrant closed a private placement with certain qualified institutional buyers and institutional accredited investors, as well as the Reporting Person, wherein the Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased. F1 · price: On April 23, 2025, the Registrant closed a private placement with certain qualified institutional buyers and institutional accredited investors, as well as the Reporting Person, wherein the Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased. Read SEC document |
| October 11, 2024 Filed Oct 17, 2024 01:56 UTC | BioCardia, Inc. BCDA · Entity 7752 | Tax withholdingCommon Stock | 11,565 | $2.65 | $30,647.25 |
DisclosureSEC source: 0001437749-24-031410 · rdgdoc.xml · nonDerivative · entry 2 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,008 F2 · shares: The reported securities represent the shares that have been withheld by the Issuer to satisfy its income tax, withholding and remittance obligations in connection with the net settlement of the RSUs vested on October 11, 2024 and does not represent a sale by the Reporting Person. F2 · price: The reported securities represent the shares that have been withheld by the Issuer to satisfy its income tax, withholding and remittance obligations in connection with the net settlement of the RSUs vested on October 11, 2024 and does not represent a sale by the Reporting Person. Read SEC document |
| October 11, 2024 Filed Oct 17, 2024 01:56 UTC | BioCardia, Inc. BCDA · Entity 7752 | GrantCommon Stock | 24,193 | $2.65 | $64,111.45 |
DisclosureSEC source: 0001437749-24-031410 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,573 F1 · shares: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock awarded as compensation in lieu of cash. 100% of the RSUs vested on October 11, 2024. F1 · price: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock awarded as compensation in lieu of cash. 100% of the RSUs vested on October 11, 2024. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:42 UTC | BioCardia, Inc. BCDA · Entity 7752 | GrantWarrant (right to buy) · Derivative | 8,333 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001437749-24-028511 · rdgdoc.xml · derivative · entry 2 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 8,333 shares Expires 2029-09-03 F1 · shares: These shares were purchased from the Issuer in a public offering that closed on September 3, 2024, wherein the Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased. F1 · price: These shares were purchased from the Issuer in a public offering that closed on September 3, 2024, wherein the Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased. F1 · derivative.underlying_shares: These shares were purchased from the Issuer in a public offering that closed on September 3, 2024, wherein the Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:42 UTC | BioCardia, Inc. BCDA · Entity 7752 | GrantCommon Stock | 8,333 | $3.00 | $24,999.00 |
DisclosureSEC source: 0001437749-24-028511 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,380 F1 · shares: These shares were purchased from the Issuer in a public offering that closed on September 3, 2024, wherein the Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased. Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 00:31 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantCommon Stock | 4,280 | $2.34 | $9,998.08 |
DisclosureSEC source: 0001437749-23-018552 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,724 F1 · shares: These shares were purchased from the issuer in a registered direct offering that closed on June 23, 2023. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 22:24 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | Tax withholdingCommon Stock | 20,676 | $1.77 | $36,596.52 |
DisclosureSEC source: 0001437749-23-016522 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,444 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested on May 18, 2023 and does not represent a sale by the Reporting Person. Read SEC document |
| May 18, 2023 Filed May 23, 2023 01:31 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantStock Option (right to buy) · Derivative | 68,265 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001437749-23-015516 · rdgdoc.xml · derivative · entry 2 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,265 Underlying: Common Stock · 68,265 shares Expires 2033-05-18 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 1/48th of the shares on June 18, 2023, and each month thereafter, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| May 18, 2023 Filed May 23, 2023 01:31 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantCommon Stock | 61,389 | $1.70 | $104,361.30 |
DisclosureSEC source: 0001437749-23-015516 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,120 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. 100% of the RSUs vested on May 18, 2023. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 13:00 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantCommon Stock | 8,928 | $1.68 | $14,999.04 |
DisclosureSEC source: 0001437749-22-029314 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,446 F1 · shares: These shares were purchased from the Issuer in a private placement that closed on December 16, 2022. Read SEC document |
| October 10, 2022 Filed Oct 11, 2022 11:01 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseCommon Stock | 2,000 | $2.07 | $4,140.00 |
DisclosureSEC source: 0001437749-22-023876 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,518 F1 · shares: This transaction was executed in multiple trades ranging from $2.06 to $2.08 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price. Read SEC document |
| May 12, 2022 Filed May 19, 2022 00:03 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | Tax withholdingCommon Stock | 20,632 | $1.32 | $27,234.24 |
DisclosureSEC source: 0001437749-22-012952 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,518 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested on April 14, 2022 and does not represent a sale by the Reporting Person. Read SEC document |
| May 12, 2022 Filed Apr 7, 2023 20:45 UTC Amendment | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantCommon Stock | 17,347 | $1.32 | $22,898.04 |
DisclosureSEC source: 0001437749-23-009766 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,803 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connections with the net settlement of RSUs vested on April 14, 2022, and does not represent a sale by the reporting person. F2 · shares: The original Form 4 incorrectly reported that 20,632 shares had been withheld due to a clerical error. The corrected number is reported herein. F3 · balance_after: The original Form 4 incorrectly reported that 76,518 shares were beneficially owned following the reported transaction. The corrected amount is reported herein. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:17 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001437749-22-009165 · rdgdoc.xml · derivative · entry 2 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-04-14 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 1/48th of the shares on May 14, 2022, and each month thereafter, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 01:17 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantCommon Stock | 50,345 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-009165 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,150 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. 100% of the RSUs vested on April 14, 2022. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 22:16 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | Tax withholdingCommon Stock | 7,274 | $4.35 | $31,641.90 |
DisclosureSEC source: 0001437749-21-014633 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,805 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested on April 21, 2021 and does not represent a sale by the Reporting Person. Read SEC document |
| April 21, 2021 Filed Apr 28, 2021 00:24 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantStock Option (right to buy) · Derivative | 75,850 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001437749-21-009942 · rdgdoc.xml · derivative · entry 2 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,850 Underlying: Common Stock · 75,850 shares Expires 2031-04-21 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 1/48th of the shares on May 21, 2021 and each month thereafter, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| April 21, 2021 Filed Apr 28, 2021 00:24 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantCommon Stock | 21,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-009942 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,079 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. 100% of the RSUs vested on April 21, 2021. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 01:16 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | Tax withholdingCommon Stock | 7,895 | $2.40 | $18,948.00 |
DisclosureSEC source: 0001437749-20-014425 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,709 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested on June 30, 2020 and does not represent a sale by the Reporting Person. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 23:19 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantStock Option (right to buy) · Derivative | 25,540 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001437749-20-008736 · rdgdoc.xml · derivative · entry 2 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,540 Underlying: Common Stock · 25,540 shares Expires 2030-04-24 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 1/48th of the shares on May 24, 2020 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 23:19 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantCommon Stock | 19,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-008736 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,292 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. 100% of the RSUs vest on June 30, 2020. Read SEC document |
| April 24, 2020 Filed Apr 29, 2020 14:36 UTC Amendment | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantCommon Stock | 19,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-008785 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,604 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. 100% of the RSUs vest on June 30, 2020. F2 · balance_after: The original Form 4 incorrectly reported the number of shares held following the reported transaction. Read SEC document |
| March 11, 2020 Filed Mar 28, 2020 01:56 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | Tax withholdingCommon Stock | 2,582 | $3.60 | $9,295.20 |
DisclosureSEC source: 0001437749-20-006390 · rdgdoc.xml · nonDerivative · entry 2 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,292 F3 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person. F2 · balance_after: This share amount reflects the number of shares beneficially owned as of the filing date of this Form 4. Read SEC document |
| August 27, 2019 Filed Mar 28, 2020 01:56 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | GrantCommon Stock | 6,315 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-006390 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,874 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. 100% of the RSUs vest on January 29, 2020. F2 · balance_after: This share amount reflects the number of shares beneficially owned as of the filing date of this Form 4. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:41 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseWarrant (right to buy) · Derivative | 16,871 | Not disclosed Strike: $6.30 | Not disclosed |
DisclosureSEC source: 0001437749-19-016067 · rdgdoc.xml · derivative · entry 4 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,871 Underlying: Common Stock · 16,871 shares Expires 2024-08-06 F1 · shares: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. F1 · price: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. F1 · derivative.underlying_shares: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:41 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | ConversionConvertible promissory note · Derivative | Not disclosed | $0.00 Strike: $3.00 | $50,000.00 |
DisclosureSEC source: 0001437749-19-016067 · rdgdoc.xml · derivative · entry 3 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 16,871 shares Expires 2020-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. F1 · reported_value: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. F1 · derivative.underlying_shares: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:41 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | ConversionCommon Stock | 16,871 | $3.00 | $50,613.00 |
DisclosureSEC source: 0001437749-19-016067 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. Read SEC document |
| July 05, 2019 Filed Aug 8, 2019 20:41 UTC | BioCardia, Inc. BCDA;BCDAW · Entity 7752 | PurchaseConvertible promissory note · Derivative | Not disclosed | $50,000.00 Strike: $8.00 | $50,000.00 |
DisclosureSEC source: 0001437749-19-016067 · rdgdoc.xml · derivative · entry 2 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 6,250 shares Expires 2020-01-05 F1 · derivative.exercise_price: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. F1 · reported_value: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. F1 · derivative.underlying_shares: These securities were issued upon automatic conversion of a Convertible Promissory Note (the "Note") purchased pursuant to a Note Purchase Agreement dated July 5, 2019, by and between the Issuer and certain investors. The principal and accrued and unpaid interest on the Note was immediately convertible into shares of common stock at $8.00 per share or, if the Note remained outstanding at the time of the closing of a public offering of the Registrant, was subject to conversion into the securities offered in the public offering at 50% of the price to the public for such securities in such offering. The Registrant closed a public offering of units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock on August 6, 2019 at a price of $6.00 per unit and the Note converted in accordance with its terms into units at a price of $3.00 per unit. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 21:40 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseCommon Stock | 1,600 | $2.56 | $4,102.40 |
DisclosureSEC source: 0001437749-18-019858 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,200 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.54 to $2.58 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 20:34 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseCommon Stock | 500 | $2.64 | $1,318.00 |
DisclosureSEC source: 0001437749-18-018346 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,600 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.58 to $2.65 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 25, 2018 Filed Sep 26, 2018 00:57 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseCommon Stock | 2,850 | $2.45 | $6,988.20 |
DisclosureSEC source: 0001437749-18-017460 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,100 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.34 to $2.59 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 22, 2018 Filed Mar 23, 2018 01:52 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseCommon Stock | 500 | $1.90 | $950.00 |
DisclosureSEC source: 0001437749-18-005274 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Read SEC document |
| March 21, 2018 Filed Mar 22, 2018 18:25 UTC | BioCardia, Inc. BCDA · Entity 7752 | PurchaseCommon Stock | 750 | $1.90 | $1,425.00 |
DisclosureSEC source: 0001437749-18-005236 · rdgdoc.xml · nonDerivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Read SEC document |
| February 01, 2018 Filed Mar 22, 2018 18:24 UTC | BioCardia, Inc. BCDA · Entity 7752 | GrantStock Option (right to buy) · Derivative | 159,020 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001437749-18-005234 · rdgdoc.xml · derivative · entry 1 McClung David · CIK 0001686155 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,020 Underlying: Common stock · 159,020 shares Expires 2028-02-01 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 1/48th of the shares on March 1, 2018 and each monthly anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.